利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

28 条记录 (耗时 0.019 秒)

    Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis
    11.
    发明申请
    Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis 有权
    用于治疗口腔粘膜炎的新型肽类似物

    公开(公告)号：US20160229890A1

    公开(公告)日：2016-08-11

    申请号：US15021889

    申请日：2014-08-11

    申请人： Soligenix, Inc.

    发明人： Oreola Donini ,  Annett Rozek ,  Jackson Lee ,  John North ,  Michael Abrams

    IPC分类号： C07K7/06 ,  A61K31/573 ,  A61K45/06 ,  A61K38/08

    CPC分类号： C07K7/06 ,  A61K31/573 ,  A61K38/08 ,  A61K45/06 ,  C07K5/1019

    摘要： Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

    摘要翻译： 化疗引起的粘膜炎，辐射诱导的粘膜炎，中性粒细胞减少性感染和结肠炎模型中获得的临床前数据表明口腔粘膜炎是先天性防御调节剂（IDR）肽的有前途的指标。 IDR在小鼠和仓鼠粘膜炎模型中获得的临床前效力结果表明，取决于化疗或放射线暴露的持续时间，每三天给药应能够以7至14次剂量覆盖粘膜炎“窗口”。 IDRs还显示了化疗引起的口腔和胃肠粘膜炎的小鼠模型的功效，与化疗和/或辐射损伤的先天免疫应答的反应一致。 IDRs在各种鼠感染模型中，在存在或不存在抗生素治疗的同时，也有效减少细菌负担并改善生存。

    Peptides and analogs for use in the treatment of oral mucositis
    13.
    发明授权
    Peptides and analogs for use in the treatment of oral mucositis 有权

    公开(公告)号：US10253068B2

    公开(公告)日：2019-04-09

    申请号：US15848746

    申请日：2017-12-20

    申请人： Soligenix, Inc.

    发明人： Oreola Donini ,  Annett Rozek ,  Jackson Lee ,  John North ,  Michael Abrams

    IPC分类号： A61K38/00 ,  C07K9/00 ,  C07K7/06 ,  C07K5/11 ,  A61K31/573 ,  A61K38/08 ,  A61K45/06

    摘要： Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

    Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis
    15.
    发明申请
    Novel Peptides and Analogs for Use in the Treatment of Oral Mucositis 审中-公开

    公开(公告)号：US20180170964A1

    公开(公告)日：2018-06-21

    申请号：US15848746

    申请日：2017-12-20

    申请人： Soligenix, Inc.

    发明人： Oreola Donini ,  Annett Rozek ,  Jackson Lee ,  John North ,  Michael Abrams

    IPC分类号： C07K7/06 ,  A61K31/573 ,  A61K38/08 ,  A61K45/06 ,  C07K5/11

    CPC分类号： C07K7/06 ,  A61K31/573 ,  A61K38/08 ,  A61K45/06 ,  C07K5/1019

    摘要： Preclinical data obtained in models of chemotherapy-induced mucositis, radiation-induced mucositis, neutropenic infection and colitis indicate oral mucositis is a promising indication for Innate Defense Regulator (IDR) peptides. Preclinical efficacy results obtained with IDRs in mouse and hamster models of mucositis indicate that dosing every third day should be able to cover the mucositis “window” with seven to fourteen doses, depending on the duration of chemotherapy or radiation exposure. IDRs have also shown efficacy in mouse models of chemotherapy-induced oral and gastrointestinal mucositis, consistent with the response of the innate immune response to chemotherapy and/or radiation damage. IDRs are also effective at reducing bacterial burden and improve survival in the presence or absence of antibiotic treatment in various murine infection models.

    Novel Peptides and Analogs for Use in the Treatment of Macrophage Activation Syndrome
    19.
    发明申请
    Novel Peptides and Analogs for Use in the Treatment of Macrophage Activation Syndrome 审中-公开
    用于治疗巨噬细胞活化综合征的新型肽和类似物

    公开(公告)号：US20150148304A1

    公开(公告)日：2015-05-28

    申请号：US14523341

    申请日：2014-10-24

    申请人： Soligenix, Inc.

    发明人： Oreola Donini ,  Christopher Schaber ,  Kevin Horgan

    IPC分类号： A61K38/08 ,  A61K31/485 ,  C07K7/06

    CPC分类号： A61K38/08 ,  A61K31/485 ,  C07K7/06 ,  A61K2300/00

    摘要： Innate Defense Regulators (IDRs) interact with intracellular signaling events and modulate the innate defense response. Whereas much of the initial work with the IDRs focused on their role in fighting infection, recent results in animal models of chemotherapy- or radiation-induced mucositis and wound healing suggest that IDRs can be beneficial during the responses to a broader range of damage-inducing agents beyond pathogens. RIVPA (SEQ ID NO. 5), has demonstrated safety in humans and efficacy in animal models of fractionated radiation-induced and chemotherapy-induced oral mucositis, in models of chemotherapy induced damage to the gastro-intestinal tract and in models of local and systemic Gram-positive and Gram-negative infection in immunocompetent and immunocompromised hosts. Based on this information, we propose the use of RIVPA (SEQ ID NO. 5) and/or other IDRs (Table 1) as a novel treatment for Macrophage Activation Syndrome.

    摘要翻译： 先天防御调节器（IDR）与细胞内信号事件相互作用，并调节天生的防御反应。 尽管与IDR的初步工作大部分集中在他们在抗击感染方面的作用，但化学疗法或放射诱导的粘膜炎和伤口愈合的动物模型中的最近结果表明，IDR在对更广泛的损伤诱导的应答期间可能是有益的 除病原体以外的药剂。 在化学诱导的胃肠道损伤模型和局部和全身模型中，RIVPA（SEQ ID NO.5）已证明人的安全性和分级放射诱导和化学诱导的口腔粘膜炎的动物模型中的功效 免疫活性和免疫受损宿主中革兰氏阳性和革兰氏阴性感染。 基于这些信息，我们提出使用RIVPA（SEQ ID NO.5）和/或其他IDR（表1）作为巨噬细胞激活综合征的新型治疗。